Chitkara University Punjab | India
Ankush Kumar is a dedicated pharmaceutical researcher whose work spans medicinal chemistry, molecular modeling, and targeted drug design with a strong focus on anticancer therapeutics. He holds a solid academic foundation with qualifications in pharmaceutical chemistry and extensive research training that includes computational drug design, structure-activity exploration, and medicinal insights into heterocyclic scaffolds. His professional experience includes serving as a Junior Research Fellow and working as an Assistant Professor across multiple academic institutions, where he contributed to teaching, mentoring, and research development. His research outputs reflect a strong contribution to oncology-oriented drug discovery, with publications covering molecular targets, biomarkers, EGFR inhibition, heterocyclic synthesis, and computational repurposing studies. He has authored numerous research papers in reputed journals, contributing to a total of 561 citations, supported by an h-index of 6 and i10-index of 4, demonstrating the growing influence of his scientific contributions. His work includes book chapters and multiple peer-reviewed articles that highlight new therapeutic strategies and structural insights into various biological targets. He has received academic distinctions such as top positions in academic competitions and has served as a reviewer for international journals, further reflecting his scholarly engagement. Overall, his research trajectory reflects a commitment to advancing pharmaceutical innovation and precision-driven drug discovery.
Profile: Google Scholar
Featured Publications
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z. S., Kumar, A., Vishakha, Jha, S. K., et al. (2023). Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular Cancer, 22(1), 105.
Kumar, A., Sehgal, A., Singh, S., Sharma, N., Yadav, S., Rashid, S., Ali, N., et al. (2023). Understanding the mechanistic pathways and clinical aspects associated with protein and gene based biomarkers in breast cancer. International Journal of Biological Macromolecules, Article 126595.
Zheng, M., Kumar, A., Sharma, V., Sehgal, A., Wal, P., Shinde, N. V., Kawaduji, B. S., et al. (2024). Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions. Frontiers in Cell and Developmental Biology, 12, Article 1353860.
Kumar, A., Kumar, B., & Bhatia, R. (2023). Design, synthesis, molecular docking, and biological evaluation of isatin-based fused heterocycles as epidermal growth factor receptor inhibitors. Assay and Drug Development Technologies, 21(5), 222–233.
Kumar, A., Narang, R. K., & Bhatia, R. (2023). Recent advancements in NS5B inhibitors (2011–2021): Structural insights, SAR studies and clinical status. Journal of Molecular Structure, 1293, Article 136272.